In a landmark decision "the Centers for Medicare & Medicaid Services("CMS") issued a proposed National Coverage Determination ("NCD") memo for autologous blood-derived products for chronic non-healing wounds. In its decision memo CMS has proposed coverage through its Coverage with Evidence Development ("CED") program for all three major wound categories: diabetic, venous and pressure wounds." CMS also, "believes that PRP may have the potential to benefit Medicare beneficiaries."
This decision marks an important turning point for platelet rich plasma and autologous blood based products in general. The value of PRP for specific clinical problems will continue to rise as data is generated supporting it for specific applications.
Read more about it via this article.